

PEX PharmaSequence monthly report - December 2018 Total open market (sell-out report)

| | | Change in comparison to | | Cumulative YTD | | Forecast | | | |
|--|------------------|-------------------------|-----------------|------------------|--------|-------------------|--------|-------------------|-------------------|
| | December 2018 | November 2018 | January 2018 | December 2017 | 2018 | Change vs 2018 | 2018 | Change vs 2017 | Change vs 2016 |
| Total turnover (PLN million) | | | | | | | | | |
| Total open market ¹ | 3 137 | 4.2% | 5.7% | 10.5% | 34 583 | 4.8% | 34 583 | 4.8% | 9.0% |
| Rx reimbursed ² | 1 038 | -1.6% | 2.0% | 4.2% | 12 178 | 4.4% | 12 178 | 4.4% | 5.9% |
| Rx nonreimbursed ³ | 653 | -0.5% | 6.5% | 13.3% | 7 509 | 3.4% | 7 509 | 3.4% | 6.7% |
| Non Rx products ⁴ | 1 428 | 11.6% | 8.9% | 14.1% | 14 635 | 5.8% | 14 635 | 5.8% | 12.8% |
| Reimbursement | | | | | | | | | |
| Reimbursement value (PLN million) | 763 | -2.0% | 4.8% | 8.7% | 8 932 | 6.1% | 8 932 | 6.1% | 10.9% |
| Reimbursement share In total turnover | 24.3% | -5.9% | -0.9% | -1.6% | 25.8% | 1.2% | 25.8% | 1.2% | 1.7% |
| Reimbursement share In reimbursed sales | 72.7% | -0.3% | 1.7% | 4.2% | 72.4% | 1.8% | 72.4% | 1.8% | 5.1% |
| Average price per pack (PLN) | | | | | | | | | |
| Total ¹ | 21.0 | -0.7% | 4.1% | 2.9% | 20.83 | 2.8% | 20.8 | 2.8% | 5.8% |
| For reimbursed Rx products ² | 28.4 | 1.4% | 3.1% | 1.5% | 28.0 | 1.9% | 28.0 | 1.9% | 3.3% |
| For nonreimbursed Rx products ³ | 25.9 | 0.8% | 4.9% | 3.9% | 25.4 | 3.2% | 25.4 | 3.2% | 9.3% |
| For Non Rx products ⁴ | 16.3 | 1.1% | 5.2% | 4.6% | 15.8 | 3.7% | 15.8 | 3.7% | 7.0% |
| Average mark-up | | | | | | | | | |
| Total ¹ | 25.0% | 0.5% | -1.4% | 1.3% | 25.0% | -0.8% | 25.0% | -0.8% | -1.7% |
| For reimbursed Rx products ² | 19.1% | 1.6% | 5.0% | 3.5% | 18.7% | 0.8% | 18.7% | 0.8% | -0.4% |
| For nonreimbursed Rx products ³ | 22.0% | 0.0% | -7.8% | -9.7% | 22.9% | -7.8% | 22.9% | -7.8% | -9.6% |
| For Non Rx products ⁴ | 29.4% | -0.9% | -0.8% | 2.9% | 29.5% | 0.2% | 29.5% | 0.2% | -1.1% |
| Average pharmacy | | | | | | | | | |
| Number of patients in pharmacies | 3 940 | 4.5% | 3.4% | 10.4% | 43 810 | 1.7% | 43 810 | 1.7% | 2.8% |
| Total turnover (PLN thousand) 1 | 214 | 4.4% | 8.9% | 13.8% | 2 320 | 5.5% | 2 320 | 5.5% | 8.4% |

- Total pharmacy turnover cumulative in PLN million -

| Total pharmacy turnover cumulative in February | | | | | | | | | | |
|--|------------|--------------------------|---------------|---|---------|------------------------------|-------------------|-------------------|--|--|
| | Pharmacy m | arket total ¹ | Rx reimbursed | k reimbursed prescriptions ² | | d prescriptions ³ | Non Rx products 4 | | | |
| 2018 | Total | Change vs 2018 | Total | Change vs 2017 | Total | Change vs 2017 | Total | Change vs 2017 | | |
| January | 2 968 | -1.8% | 1018 | 3.6% | 613 | -2.7% | 1312 | -5.4% | | |
| February | 5 784 | 0.3% | 1 950 | 0.9% | 1 2 1 6 | -0.4% | 2 575 | 0.0% | | |
| March | 8 896 | 1.7% | 3 024 | 1.0% | 1879 | -0.6% | 3 929 | 3.3% | | |
| April | 11 531 | 0.8% | 3 981 | 0.5% | 2 471 | -1.2% | 4 992 | 1.8% | | |
| May | 14 152 | 0.3% | 4 9 3 6 | 0.2% | 3 057 | -1.8% | 6 051 | 1.3% | | |
| June | 16 943 | 1.2% | 6 023 | 1.9% | 3 680 | -0.3% | 7 110 | 1.2% | | |
| July | 19 653 | 2.0% | 7 003 | 2.5% | 4 288 | 0.5% | 8 208 | 2.2% | | |
| August | 22 432 | 2.7% | 7 983 | 3.0% | 4 905 | 1.1% | 9 368 | 3.2% | | |
| September | 25 254 | 2.9% | 8 962 | 3.1% | 5 509 | 1.3% | 1 059 | 3.3% | | |
| October | 28 434 | 3.8% | 10 085 | 4.0% | 6 201 | 2.1% | 11 928 | 4.3% | | |
| November | 31 446 | 4.3% | 11 140 | 4.4% | 6 857 | 2.6% | 13 207 | 5.0% | | |
| December | 34 583 | 4.8% | 12 178 | 4.4% | 7 509 | 3.4% | 14 634 | 5.8% | | |

Retail sales in PLN

PEX PharmaSequence Sp. z o.o., ul. Kłobucka 23, 02-699 Warszawa tel. 022-886-47-15, fax. 022-638-21-29


e-mail: biuro@pexps.pl http://www.pexps.pl pex PharmaSequence

Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy, KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł.


pex

PEX PharmaSequence monthly report - December 2018 Trends

- Total monthly pharmacy sales in PLN million -



- Total monthly sales in an average pharmacy in PLN -



Retail sales in PLN

PEX PharmaSequence Sp. z o.o., ul. Kłobucka 23, 02-699 Warszawa tel. 022-886-47-15, fax. 022-638-21-29 e-mail: biuro@pexps.pl http://www.pexps.pl

Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy, KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł






PEX PharmaSequence monthly report - December 2018 Average pharmacy

| | December'18 | YTD'2018 | November'18 | Change | | December'17 | Change | | YTD'2017 | Change | |
|--|-------------|----------|-------------|--------|-------|-------------|--------|-------|----------|--------|-------|
| | | | | Value | % | | Value | % | | Value | % |
| Total turnover (thousand PLN) | | | | | | | | | | | |
| Total open market ¹ | 214 | 2 320 | 205 | 9.0 | 4.4% | 188 | 26.0 | 13.8% | 2 200 | 120.5 | 5.5% |
| Rx reimbursed ² | 71 | 817 | 72 | -1.0 | -1.4% | 66 | 4.9 | 7.4% | 778 | 39.0 | 5.0% |
| Rx nonreimbursed ³ | 45 | 504 | 45 | -0.1 | -0.3% | 38 | 6.4 | 16.7% | 484 | 19.6 | 4.1% |
| Non Rx products ⁴ | 97 | 982 | 87 | 10.3 | 11.9% | 83 | 14.5 | 17.5% | 922 | 59.7 | 6.5% |
| Average price ⁵ per pack (PLN) | | | | | | | | | | | |
| Total ¹ | 21.0 | 20.8 | 21.1 | -0.14 | -0.7% | 20.4 | 0.6 | 2.9% | 20.3 | 0.5 | 2.7% |
| For reimbursed Rx products ² | 28.4 | 28.0 | 28.0 | 0.4 | 1.4% | 28.0 | 0.4 | 1.5% | 27.5 | 0.5 | 1.9% |
| For nonreimbursed products ³ | 25.9 | 25.4 | 25.7 | 0.2 | 0.8% | 24.9 | 1.0 | 3.9% | 24.6 | 0.8 | 3.1% |
| For Non Rx products ⁴ | 16.3 | 15.8 | 16.1 | 0.2 | 1.1% | 15.6 | 0.7 | 4.6% | 15.2 | 0.6 | 3.7% |
| Average mark-up* | | | | | | | | | | | |
| Total ¹ | 25.0% | 25.01% | 24.9% | 0.1% | 0.5% | 24.7% | 0.3% | 1.3% | 25.3% | -0.3% | -1.0% |
| For reimbursed Rx products ² | 19% | 18.6% | 18.8% | 0.3% | 1.6% | 18.5% | 0.7% | 3.5% | 18.5% | 0.1% | 0.6% |
| For nonreimbursed Rx products ³ | 22% | 23.0% | 22.0% | 0.0% | 0.0% | 24.4% | -2.4% | -9.7% | 24.9% | -1.9% | -7.6% |
| For Non Rx products ⁴ | 29% | 29.5% | 29.7% | -0.3% | -0.9% | 28.6% | 0.8% | 2.9% | 29.5% | 0.0% | 0.0% |
| Number of patients | | | | | | | | | | | |
| Total ¹ | 3 940 | 43 810 | 3 770 | 170 | 4.5% | 3 570 | 370 | 10.4% | 43 080 | 730 | 1.7% |
| For reimbursed Rx products ² | 740 | 8 590 | 750 | -10 | -1.3% | 690 | 50 | 7.2% | 8 520 | 70 | 0.8% |
| For nonreimbursed Rx products ³ | 780 | 8 950 | 780 | 0 | 0.0% | 730 | 50 | 6.8% | 9 320 | -370 | -4.0% |
| For Non Rx products ⁴ | 3 330 | 36 500 | 3 130 | 200 | 6.4% | 2 990 | 340 | 11.4% | 35 710 | 790 | 2.2% |
| Number of pharmacies - summary# | | | | | | | | | | | |
| | 14 530 | 14 807 | 14 639 | -109 | -0.7% | 14 969 | -439 | -2.9% | 14 948 | -141 | -0.9% |

^{*}Values in "Change – value" for average mark-up in percentage points " Number of pharmacies based on PEX's analysis.

- Pharmacies on the open market -



Retail sales in PLN

PEX PharmaSequence Sp. z o.o., ul. Kłobucka 23, 02-699 Warszawa tel. 022-886-47-15, fax. 022-638-21-29 e-mail: biuro@pexps.pl http://www.pexps.pl


pex PharmaSequence

Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy, KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł



PEX PharmaSequence monthly report - December 2018 Price

- Structure of the average retail price⁵ -



All amounts are retail open pharmacy sales in PLN

Most important terms:

- ¹ Total open pharmacy market sales
- $^{\rm 2}$ Total sales of Rx products covered by NHF reimbursement
- $^{\rm 3}$ Total sales of Rx products not covered by NHF reimbursement
- ⁴ Total sales of products available without prescription, including OTC medicines, food supplements, herbs, patches, medical devices, etc.
- ⁵ The calculation of the average price is based on products categorized and included in the pharmacy data database operated by PEX PharmaSequence and Kamsoft (Omnibus) they make up 97% of the pharmacy market.

PEX PharmaSequence Sp. z o.o., ul. Kłobucka 23, 02-699 Warszawa tel. 022-886-47-15, fax. 022-638-21-29 e-mail: biuro@pexps.pl http://www.pexps.pl





PEX PharmaSequence monthly report - December 2018 PEX PharmaSequence commentary

The pharmacy market in December 2018 saw sales go close to 3 137m PLN. Value of sales compared to December 2017 grew by over 298m PLN (+10.5%). Compared to November of 2018, sales grew by approximately 125m PLN (+4.2%).

Compared to the same period of 2017 the value of tracked segments was growing. The non-prescription segment grew by 176.1m PLN (+14.1%). Sales based on non-reimbursed prescriptions grew by approximately 76.5m PLN (+13.3%) and on reimbursed prescriptions grew by 42.2m PLN (+4.2%).


Compared to the previous month, value of products sold without a prescription was higher by approximately 148.5m PLN (+11.6%). Value of non-reimbursed prescriptions was lower by almost 16.9m PLN (-1.6%) and of reimbursed Rx drugs slightly fell by 3.3m PLN (-0.5%).

The average retail drug price in December 2018 was approximately 21 PLN and was 0.7% smaller than in the previous month, and 2.9% higher than the average price in December of 2017. The average retail price of reimbursed prescriptions was 28.4 PLN (+1.5% vs December 2017), 25.9 PLN for non-reimbursed prescriptions (+3.9% vs December 2017) and 16.3 PLN for products sold without a prescription (+4.6% vs December 2017).

Average pharmacy margin for all drugs in December 2018 was 25% and was higher by about 0.5pp than the margin in the same period of 2017. Compared to November of 2018, the average pharmacy margin grew by approximately 0.1pp.

Drug reimbursement by the National Health Fund in December was in the amount over 763m PLN, 8.7% more than in the same period of 2017. The level of patient copayment for reimbursed drugs in December was 26.4%, lower by 0.3 pp. compared to previous month.





PEX PharmaSequence Sp. z o.o., ul. Kłobucka 23, 02-699 Warszawa tel. 022-886-47-15, fax. 022-638-21-29 e-mail: biuro@pexps.pl http://www.pexps.pl






PEX PharmaSequence monthly report - December 2018

About us

PEX PharmaSequence is a Polish **consulting and research** company with its own wide-ranging resources of market data. We specialize in services for entities operating in the broadly defined healthcare market.

As a result of numerous projects, carried out over **almost 20 years** of the company's operations on the Polish market, for innovative, generic, and OTC producers, PEX PharmaSequence has gained unique expertise that allows us to provide our Clients with valuable support.



It is not without significance that our team, comprising **60+ people**, has the benefit of experience gained in service companies specializing in the pharma sector, as well as industry experience acquired in local and global pharmaceutical companies.

Our expertise and competencies as well as our knowledge of the Polish pharma market enable us to develop proposals and efficiently carry out projects, which offer added value to our Clients' business decisions.

We would like to hear from you!



Published on the 16th of January 2019, prepared by Elżbieta Brzeźny, Analyst based on PEX PharmaSequence data.

pex PharmaSequence

The copyright to this document belongs to PEX PharmaSequence Sp. z o.o., headquartered in Warsaw. The contents of this document are not a result of a provided service and PEX PharmaSequence Sp. z o.o. is not responsible to third parties using this document, on any legal basis, for any action taken or not taken, including for decisions made based on information provided. Quoting parts of the document requires indicating PEX PharmaSequence Sp. z o.o. as the author.

PEX PharmaSequence Sp. z o.o.

el.: (+48) 22 886 47 15 ax (+48) 22 638 21 29

biuro@pexps.pl